JP2024543377A - 造血前駆体キナーゼの二官能性分解物質およびその治療的使用 - Google Patents

造血前駆体キナーゼの二官能性分解物質およびその治療的使用 Download PDF

Info

Publication number
JP2024543377A
JP2024543377A JP2024527355A JP2024527355A JP2024543377A JP 2024543377 A JP2024543377 A JP 2024543377A JP 2024527355 A JP2024527355 A JP 2024527355A JP 2024527355 A JP2024527355 A JP 2024527355A JP 2024543377 A JP2024543377 A JP 2024543377A
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
inhibitors
compound
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024527355A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024543377A5 (cg-RX-API-DMAC7.html
Inventor
ラン ワン,
マーク エドワード ザック,
ジョン ビューエル,
フレデリック コーエン,
ライアン ペンバートン,
ハンター ピー. シュナトナ,
Original Assignee
ニューリックス セラピューティクス,インコーポレイテッド
ギリアード サイエンシーズ, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニューリックス セラピューティクス,インコーポレイテッド, ギリアード サイエンシーズ, インコーポレイテッド filed Critical ニューリックス セラピューティクス,インコーポレイテッド
Publication of JP2024543377A publication Critical patent/JP2024543377A/ja
Publication of JP2024543377A5 publication Critical patent/JP2024543377A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2024527355A 2021-11-10 2022-11-09 造血前駆体キナーゼの二官能性分解物質およびその治療的使用 Pending JP2024543377A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163263875P 2021-11-10 2021-11-10
US63/263,875 2021-11-10
PCT/US2022/049426 WO2023086399A1 (en) 2021-11-10 2022-11-09 Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof

Publications (2)

Publication Number Publication Date
JP2024543377A true JP2024543377A (ja) 2024-11-21
JP2024543377A5 JP2024543377A5 (cg-RX-API-DMAC7.html) 2025-11-07

Family

ID=85132852

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024527355A Pending JP2024543377A (ja) 2021-11-10 2022-11-09 造血前駆体キナーゼの二官能性分解物質およびその治療的使用

Country Status (12)

Country Link
US (2) US12091426B2 (cg-RX-API-DMAC7.html)
EP (1) EP4430052A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024543377A (cg-RX-API-DMAC7.html)
KR (1) KR20240101654A (cg-RX-API-DMAC7.html)
CN (1) CN118510786A (cg-RX-API-DMAC7.html)
AR (1) AR127625A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022388571A1 (cg-RX-API-DMAC7.html)
CA (1) CA3235913A1 (cg-RX-API-DMAC7.html)
IL (1) IL312361A (cg-RX-API-DMAC7.html)
MX (1) MX2024005431A (cg-RX-API-DMAC7.html)
TW (1) TW202334170A (cg-RX-API-DMAC7.html)
WO (1) WO2023086399A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024008868A (es) 2022-01-18 2024-09-23 Maze Therapeutics Inc Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso.
WO2025029995A1 (en) * 2023-08-01 2025-02-06 Arvinas Operations, Inc. Hpk1 targeting compounds and uses thereof
CN117126133B (zh) * 2023-08-14 2026-06-30 中国海洋大学 一种化合物及其用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020092621A1 (en) * 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
WO2020092528A1 (en) * 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
WO2020227325A1 (en) * 2019-05-06 2020-11-12 Icahn School Of Medicine At Mount Sinai Heterobifunctional compounds as degraders of hpk1
WO2021057872A1 (zh) * 2019-09-25 2021-04-01 珠海宇繁生物科技有限责任公司 一种protac小分子化合物及其应用
JP7857232B2 (ja) * 2020-05-06 2026-05-12 ニューリックス セラピューティクス,インコーポレイテッド 造血前駆体キナーゼの二官能性分解物質およびその治療的使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA031601B1 (ru) 2013-07-31 2019-01-31 Джилид Сайэнс, Инк. Ингибиторы syk
US11065231B2 (en) 2017-11-17 2021-07-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
US20200038513A1 (en) 2018-07-26 2020-02-06 Arvinas Operations, Inc. Modulators of fak proteolysis and associated methods of use
MX2021001957A (es) 2018-08-22 2021-07-15 Cullgen Shanghai Inc Compuestos de degradacion y metodos de uso del receptor de tropomiosina quinasa (trk).
JP7815127B2 (ja) 2020-02-19 2026-02-17 ニューリックス セラピューティクス,インコーポレイテッド インターロイキン-1受容体関連キナーゼの二機能性分解剤およびその治療的使用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020092621A1 (en) * 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
WO2020092528A1 (en) * 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
WO2020227325A1 (en) * 2019-05-06 2020-11-12 Icahn School Of Medicine At Mount Sinai Heterobifunctional compounds as degraders of hpk1
WO2021057872A1 (zh) * 2019-09-25 2021-04-01 珠海宇繁生物科技有限责任公司 一种protac小分子化合物及其应用
JP7857232B2 (ja) * 2020-05-06 2026-05-12 ニューリックス セラピューティクス,インコーポレイテッド 造血前駆体キナーゼの二官能性分解物質およびその治療的使用

Also Published As

Publication number Publication date
US20240018162A1 (en) 2024-01-18
IL312361A (en) 2024-06-01
WO2023086399A1 (en) 2023-05-19
US20240400587A1 (en) 2024-12-05
KR20240101654A (ko) 2024-07-02
MX2024005431A (es) 2024-07-19
CA3235913A1 (en) 2023-05-19
EP4430052A1 (en) 2024-09-18
AU2022388571A1 (en) 2024-05-09
AR127625A1 (es) 2024-02-14
US12091426B2 (en) 2024-09-17
TW202334170A (zh) 2023-09-01
CN118510786A (zh) 2024-08-16

Similar Documents

Publication Publication Date Title
US11739101B2 (en) Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof
AU2021411587B2 (en) Indazole compounds as kinase inhibitors
JP6942896B2 (ja) Parp7阻害剤としてのピリダジノン
JP7820584B2 (ja) インターロイキン-1受容体関連キナーゼの二官能性分解剤及びその治療的使用
TW202413351A (zh) 藉由irak4抑制劑與e3連接酶配體的軛合降解irak4及使用方法
US12091426B2 (en) Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof
SG187747A1 (en) Inhibitors of bruton's tyrosine kinase
TW202448898A (zh) 用於egfr激酶降解之化合物
TW202328129A (zh) 治療自體免疫疾病之吡唑并[3,4—b]吡啶化合物
HK40115438A (en) Bifunctional degradation agents of hematopoietic progenitor cell kinases and therapeutic uses thereof
CN120957981A (zh) 基于2,4-二苯胺嘧啶的Aurora-A激酶选择性降解诱导化合物
CN115557946A (zh) 杂环内酰胺类化合物,包含其的药物组合物及其用途
HK40121612A (en) Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof
OA21863A (en) Indazole based compounds and associated methods of use.
CN117396477A (zh) 用于治疗癌症的经吡啶基取代的氧代异吲哚啉化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251029

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251029

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260710

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260717